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Introduction: Survival of patients with acquired immune deﬁciency syndrome has improved
with  combination antiretroviral therapy; mortality due to liver diseases, however, has also
increased  in these patients.
Objectives:  To estimate the accumulated probability of survival in human immunodeﬁciency
virus–hepatitis C virus coinfected and non-coinfected patients and to investigate factors
related  to acquired immune deﬁciency syndrome patients’ survival.
Methods:  Non-concurrent cohort study using data from surveillance information systems
of  acquired immune deﬁciency syndrome patients over 13 years of age. Hepatitis C and B,
human  immunodeﬁciency virus exposure category, CD4+ T cell count, age group, schooling,
race,  sex, and four acquired immune deﬁciency syndrome diagnosis periods were  studied.
Kaplan–Meier  survival analysis and Cox model with estimates of the hazard ratio and 95%
conﬁdence  interval were used.
Results: Of the total 2864 individuals included, with median age was  35 years, 219 died
(7.5%),  and 358 (12.5%) were human immunodeﬁciency virus–hepatitis C virus coinfected.
The  accumulated probability of survival in human immunodeﬁciency virus–hepatitis C virus
coinfected patients, after acquired immune deﬁciency syndrome diagnosis, at 120 months,
was 0%, 38.9%, 83.8% in 1986–1993, 1994–1996, 1997–2002, respectively, and 92.8% at 96
months  in 2003–2010; survival in non-coinfected patients at 120 months was 80%, 90.2%,94%  in 1986–1993, 1994–1996, 1997–2002, respectively, and 94.1% at 96 months in 2003–2010.
In  the multivariate model the following variables were predictive of death: hepatitis C viruscoinfection (hazard ratio = 2.7; conﬁdence interval 2.0–3.6); Hepatitis B virus coinfection
(hazard  ratio = 2.4; conﬁdence interval 1.7–3.6); being ≥50 years old (hazard ratio = 2.3; conﬁ-
dence  interval 1.3–3.8); having 8–11 years of schooling (hazard ratio = 1.6; conﬁdence interval
 Study performed at Faculdade de Saúde Pública, Universidade de São Paulo.
∗ Corresponding author at: Rua Santa Cruz, 81, Vila Mariana, São Paulo, SP, 04121-000, Brazil.
E-mail address: wong@crt.saude.sp.gov.br (W.K. Alencar).
1413-8670© 2013 Elsevier Editora Ltda. 
http://dx.doi.org/10.1016/j.bjid.2013.06.006
Este é um artigo Open Access sob a licença de CC BY-NC-ND
b r a z j i n f e c t d i s . 2 0 1 4;1 8(2):150–157  151
1.1–2.3), having 4–7 years of schooling (hazard ratio = 1.9; conﬁdence interval 1.3–2.8) and
having up to 3 years of schooling (hazard ratio = 3.3; conﬁdence interval 2.0–5.5).
Conclusions:  Among patients diagnosed after 1996, there was a signiﬁcant increase in the
cumulative probability of survival in human immunodeﬁciency virus–hepatitis C virus coin-
fected individuals; among those diagnosed with acquired immune deﬁciency syndrome
from 2003 to 2010, this probability was similar between coinfected and non-coinfected
patients.
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he United Nations Program on human immunodeﬁciency
irus/acquired immune deﬁciency syndrome (HIV/AIDS)
tates that “globally, 34.0 million (31.4 million–35.9 million)
eople  were  living with HIV at the end of 2011”, or 0.8% of
dults  aged 15–49 years.1 Survival of patients living with the
IDS  has increased in the highly active antiretroviral ther-
py  (HAART) era, currently called combination antiretroviral
herapy (cART).2
In Brazil, the median survival time estimated was  5.1
onths between 1982 and 19893 and increased to 58 months
n  1996;4 in the south and southeast regions of Brazil, 59.4% of
IDS  patients survived 108 months in 1998–1999,5 and in São
aulo,  the accumulated probability of survival was  72% at 108
onths  in 1997–2003.6
Although cART has brought longer survival to HIV-infected
atients, the morbidity and mortality due to viral hepatitis,
specially type C, has also increased.7,8 It is estimated that
bout  one-third of HIV-infected individuals in the world have
epatitis  C virus (HCV) coinfection.9 In fact, decompensated
iver disease due to HCV has increased as cause of death
n  patients with HIV–HCV coinfection,7 and the prevalence
f  cirrhosis10 and of deaths due to hepatocellular carcinoma
ave also been increasing in HIV-infected patients.10
The objective of the present study was  to estimate the
umulative probability of survival after AIDS diagnosis in
IV–HCV-coinfected and non-coinfected patients and to per-
orm  exploratory analysis to investigate factors related to AIDS
atients’ survival.
ethods
his is a longitudinal observational study, based on medi-
al  records, of a non-concurrent cohort, of patients receiving
are  in a public referral center for the treatment of sexually
ransmitted diseases and AIDS in São Paulo city, Brazil (CRT
ST/AIDS-SP, CRT). This clinic has also become a referral cen-
er  for hepatitis treatment since 2004, and it is also the head
fﬁce  of the São Paulo State Program for Sexually Transmitted
iseases and AIDS.
The  Metropolitan Region of São Paulo city had, in 2010,
 population of 19.667.558 inhabitants according to local
11 12
© 20ensus, and 74,308 AIDS cases notiﬁed from 1980 to 2009.
he sample included in this study comprises all AIDS cases in
ndividuals aged 13 years or older being followed in our referral
enter,  and with complete medical records.Patients were excluded from the present study if he/she
had  a diagnosis of AIDS related complex (syndrome including
fatigue  and swollen lymph nodes) or if the death certiﬁcate
stated AIDS as the cause of death without a laboratory exam
to  conﬁrm HIV infection. These cases were  more  common
before  1996, especially before 1987 (HIV viruses were  identi-
ﬁed  in 1983 and 1986).13–15 Pregnancy was  also a criteria of
exclusion in this study.
For  the purpose of inclusion in this study, HCV infection
was deﬁned by serological tests (ELISA or EIA, in any genera-
tion)  and the qualitative or quantitative detection of HCV RNA,
by  the time of AIDS diagnosis or in the nearest date (up to two
years  before or after).
The  sources of data in this study were the national notiﬁca-
tion  databases for AIDS cases (SINAN Windows up to 2006 and
SINAN  Net from 2007 on), the CRT-Epidemiological Surveil-
lance  System, and the CRT-Laboratory System. A fourth source
was  the São Paulo State surveillance system, called BIP-AIDS
(integrating SIM, Sistema de Informac¸ão  sobre Mortalidade,
civil notary ofﬁces and SEADE Foundation, Fundac¸ão  Sistema
Estadual  de Análise de Dados). When some information was
not  available in these electronic systems, it was  searched
directly from medical records.
A special spreadsheet was  created for data collection
including the following independent variables: AIDS diagno-
sis  periods (1986–1993, 1994–1996, 1997–2002 and 2003–2010),
patient’s age, gender, ethnicity/race, years of schooling, CD4+
T  cell count at AIDS diagnosis, HCV infection and hepatitis B
surface  antigen (HBsAg) in a period next to AIDS diagnosis (up
to  two years before or after). The elapsed time from diagnosis
until  death, in months, was  taken as the dependent variable.
The  source of exposure to HIV was  registered in three cat-
egories:  from heterosexual relationship, men  who have sex
with  men  (MSM), and by the use of intravenous drugs (IDU).
Transmission by blood transfusions, accidents and others
were  excluded from the survival analysis. When information
was  initially registered as “unknown”, the original medical
record  in the clinic was  searched manually for completion.
The  ﬁnal date for survival calculation was  established as
April  30, 2011. Loss to follow up and death by other-than-AIDS
or unknown causes were censored (incomplete follow up).
Statistical  analysis
lsevier Editora Ltda.Este é um artigo Open Access sob a licença de CC BY-NC-NDInitially, a descriptive analysis was  performed, presenting
absolute and relative frequencies, comparing patients
infected and uninfected with HCV, observing distributions
and  characteristics of users in relation to the study variables
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Fig. 2 – Survival analysis of AIDS patients according to theJuly  1986–April 2010).
of interest. Chi-square test was  used to compare infected and
uninfected  cases by HCV.
Kaplan–Meier analysis of survival was  performed, with a
cumulative  probability of survival with AIDS estimated in
months,  according to each variable of interest and period of
diagnosis  of AIDS. Statistical signiﬁcance was  assessed by
the  log rank test. A Cox regression or proportional hazards
model  was  chosen to calculate risk or hazard ratio (HR) in
survival  analysis, with a conﬁdence interval (CI) of 95%, and
the  variable “period of diagnosis” was  used as a stratum.
Univariate analysis was  followed by multivariate analysis.
Associations were considered statistically signiﬁcant with a
signiﬁcance level of less than 5%. Microsoft Excel 2003 and
STATA  software, version 10.0, were used for the statistical
analysis.
The  study protocol was  designed in accordance with the
National  Health Committee guidelines, and was  approved by
CRT’s and Faculdade de Saúde Pública – São Paulo University’s
Ethics Committees with the protocol number CRT 002/2010
and  FSP-USP 44/2010.
Results
From July 1986 to April 2010, a total of 19,475 AIDS cases were
registered  in the major national databases (SINAN Windows
and  Net). However, 14,050 needed to be excluded from the
study  for the reasons shown in Fig. 1 and described in detail
below.  The remaining 5425 AIDS cases were  therefore assessed
for  eligibility: 2561 were  further excluded because they died in
ﬁrst year of follow-up after AIDS diagnosis, because they did
not  fulﬁll the criteria for AIDS characterization, or because of
problems  with the medical records (such as the lack of an iden-
tifying  number). Another reason for exclusion was  the lack of
a  HCV RNA test for hepatitis C conﬁrmation (hepatitis was
registered  as cirrhosis). Therefore, this study is based on 2864
cases  of AIDS patients, among whom 358 were coinfected with
HCV.
The  reasons for exclusions were: lack of laboratory exams
in  the database; medical records bringing information of AIDSperiod  of AIDS diagnosis.
only in the death certiﬁcate, or, otherwise, alleged ARC symp-
toms  in the death certiﬁcate, without clinical or lab exams;
cases  not registered in the CRT Epidemiological surveillance
system database, which contains follow-up data; patients
being  followed-up in other institutions, admitted in hospitals,
or  subjects of clinical research protocols; inconclusive sero-
logy  and ﬁnally, patients were  excluded when the period for
data  collection was  ﬁnished.
Table  1 summarizes the patients’ demographic and clini-
cal  characteristics among the 2864 AIDS cases, infected or not
with  HCV.
In  our study, 76.3% of the patients were  men, 70.8% of
white  race, 69.2% aged 30–49 years with a median age of 35
years  (minimum 13 and maximum 79), 58.2% with 4–11 years
of  schooling, 54.1% were MSM, 93.7% had CD4+ T cell count
<350  cell/mm3, 12.5% were HIV–HCV coinfected, 7.5% had Hep-
atitis  B, and 44.2% of patients were AIDS diagnosed in the
1997–2002  period.
Regarding schooling years, 42% of coinfected individuals
had 4–7 years of schooling while 40.1% of non-coinfected
patients had 12 school years or more.  The IDU HIV exposure
category was identiﬁed in 45.1% among coinfected subjects
while  58.6% of non-coinfected was  MSM. Hepatitis B was
more  common in non-coinfected HIV–HCV (8.1% versus 3.6%;
p  = 0.003).
Among the 2864 AIDS patients, 219 (7.6%) died between
1986 and 2010.
Fig.  2 shows the Kaplan–Meier survival curves of the
patients according to the AIDS diagnosis period. A higher
rate  of survival was  seen in the post-cART: 1997–2002 and
2003–2010  AIDS diagnosis period (log rank = 71.3; p < 0.001).
Fig. 3 shows the survival analysis of monoinfected and
HIV–HCV  coinfected AIDS patients according to AIDS diag-
nosis  period. The accumulated probability of survival among
coinfected  patients at 120 months after AIDS diagnosis was
0%  for those diagnosed in the period between 1986 and 1993,
38.9%  in 1994–1996 and 83.8% in the 1997–2002 period. Sur-
vival  in non-coinfected patients at 120 months was 80%, 90.2%,
94%  in 1986–1993, 1994–1996, 1997–2002, respectively. Finally,
in  the 2003–2010 AIDS diagnosis period, because of a shorter
observation time, the survival among coinfected was 92.8%
and  among non-coinfected was  94.1% at 96 months.
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Table 1 – Characteristics of patients according to HCV infection (CRT-DST/AIDS-SP, 1986–2010).
Patients’ characteristics Cohort pa
AIDS
(n  = 2.506)
AIDS/HCV
(n = 358)
Total
(n = 2.864)
n % n % n %
Sex
Female 594 23.7 84 23.5 678 23.7 0.920
Male 1.912 76.3 274 76.5 2.186 76.3
Raceb
White 1.764 70.8 253 70.9 2.017 70.8 0.983
Non-white 727 29.2 104 29.1 831 29.2
Age rangec
Up to 29 years old 604 24.0 82 22.9 686 24.0 0.732
30–49 years old 1.729 69.0 254 70.9 1.983 69.2
50 years or older 173 6.9 22 6.1 195 6.8
Agec
Median 35 35 35
Inter-  quartile range (25%–75%) 30–41 30–41 30–41
Minimum 13 20 13
Maximum 79 76 79
Education  (years)c,d
Up to 3 95 3.9 36 10.1 131 4.7 <0.001
4–7 490  20.0 150 42.0 640 22.8
8–11 881 36.0 112 31.4 993 35.4
12 or more 983 40.1 59 16.5 1.042 37.1
HIV exposure categoryc,e,f
Heterosexual 924 37.5 112 31.7 1.036 36.8 <0.001
MSM 1.443 58.6 82 23.2 1.525 54.1
IDU 96 3.9 159 45.1 255 9.1
CD4+ T cell countc,g
<350 cell/mm3 2.218 93.8 295 93.1 2.513 93.7 0.598
≥350 cell/mm3 146 6.2 22 6.9 168 6.3
Hepatitis B (HBsAg)c
No 2.303 91.9 345 96.4 2.648 92.5 0.003
Yes 203 8.1 13 3.6 216 7.5
Period of AIDS diagnosis
2003–2010  1.090 43.5 71 19.8 1.161 40.5 <0.001
1997–2002 1.047 41.7 218 60.9 1.265 44.2
1994–1996 302 12.1 61 17.1 363 12.7
1986–1993 67 2.7 8 2.2 75 2.6
MSM, men who have sex with men; IDU, injecting drug users; HBsAg, surface antigen of hepatitis B.
a Concerning the comparison of the groups (Pearson).
b Data ignored = 16.
c The diagnosis of AIDS.
d Data ignored = 58.
e Data ignored = 46.
f 2 Cases were excluded transfusion.
g Data ignored = 183.
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5Results of Cox univariate analysis are presented in Table 2.
CV  coinfection was  a predictor of death (HR = 2.9, CI 2.1–3.8).
ther  predictors of death were:  Hepatitis B virus (HBV) coinfec-
ion  (HR = 2.1, CI 1.4–3.0), having up to three years of schooling
HR  = 4.0, CI 2.4–6.6), having four to seven years of schooling
HR  = 2.4, CI 1.6–3.5), having 8–11 years of schooling (HR = 1.7, CI
.1–2.4),  IDU exposure category (HR = 1.8, CI 1.3–2.7), and being
0  years or older (HR = 2.0, CI 1.2–3.4).The  ﬁnal multivariate Cox regression model is presented in
Table  3. The predictive variables of death, adjusted for other
variables,  were: HCV coinfection (HR = 2.7, CI 2.0–3.6), HBV
coinfection (HR = 2.4, CI 1.7–3.6), having 8–11 years of schooling
(HR  = 1.6, CI 1.1–2.3), having four to seven years of schooling
(HR  = 1.9, CI 1.3–2.8), having up to three years of schooling
(HR = 3.3, CI 2.0–5.5), and being 50 years or older (HR = 2.3, CI
1.3–3.8).
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Table 2 – Univariate Cox model analysis of predictive variables of death, CRT DST/AIDS-SP, 1986–2010.
Patient’s characteristics AIDS n = 2864 Death n = 219 HR 95% CI p-Value
Sex
Male 2.186 176 1 – –
Female 678 43 0.8 0.6–1.1 0.149
Agea
Up to 29 years old 686 49 1 – –
30–49 years old 1.983 147 1.1 0.8–1.6 0.480
50 years old or older 195 23 2.0 1.2–3.4 0.005
Skin colorb
White 2.017 163 1 – –
Non-white 831 56 0.8 0.6–1.1 0.285
HIV exposure categorya,c,d
Heterosexual 1.036 81 1 – –
MSM 1.525 94 0.8 0.6–1.0 0.083
IDU 255 42 1.8 1.3–2.7 0.001
Schooling (years)a,e
12 or more 1.042 43 1 – –
8–11 993 74 1.7 1.1–2.4 0.009
4–7 640 75 2.4 1.6–3.5 <0.001
Up to 3 131 25 4.0 2.4–6.6 <0.001
T CD4+a,f cell count
≥ 350 cell/mm3 168 12 1 – –
< 350 cell/mm3 2.513 196 0.7 0.4–1.3 0.308
Hepatitis B (HBsAg)b
No 2.648 185 1 – –
Yes 216 34 2.1 1.4–3.0 <0.001
Hepatitis Cb
No 2.506 154 1 – –
Yes 358 65 2.9 2.1–3.8 <0.001
MSM, men who have sex with men; IDU, injecting drug users; HBsAg, hepatitis B surface antigen; HR, hazard ratio; CI, conﬁdence interval.
a In the diagnosis of AIDS.
b Unknown data = 16.
c Unknown data = 46.
d 2 cases were excluded due to blood transfusion.
e Unknown data = 58.
f Unknown data = 183.
Discussion
Concurrent infection by two or more  agents is more  harmful
to  human health.16
HIV–HCV coinfection was  independently associated with
increased  risk of death in this study. Branch et al. have found
50%  increased mortality among coinfected patients compared
with  non-coinfected.17 Although some other studies have
not  observed the same association,18 recent studies have
consistently shown the burden of death among coinfected
individuals.19–21
As already seen in other studies,4 the time of AIDS diagno-
sis  was  signiﬁcantly associated with survival in our study. This
is probably due to cART, which has changed the natural his-
tory  of and clinical evolution of HIV infection and is available
free-of-charge for Brazilian patients, distributed by the public
health  system since 1996.22The survival curves in our study were signiﬁcantly dif-
ferent  between HCV–HIV coinfected and non-coinfected
patients, a result similar to that of Bonacini et al.23 However,this  difference was not signiﬁcant for the periods of AIDS
diagnosis between 2003 and 2010. This result can be explained
by  the immunosuppression control in patients undergoing
cART24 and by the inclusion, in 2002, of pegylated interferon
for  treating hepatitis C in Brazil.25
In our study CD4+ T cell count was  not associated with sur-
vival.  Peters et al. have found that hepatitis C virus coinfection
does  not inﬂuence CD4+ T cell count recovery in HIV-1 infected
patients  with maximum virologic suppression.26 Neverthe-
less,  by improving immune function, cART can slower the
clinical  evolution of HCV infection27 and reduce signiﬁcantly
the  rate of deaths related to hepatitis C liver disease.28
The use of illicit injected drugs is known to be a risk factor
for  HCV infection. In our study, drug use was not indepen-
dently associated with death, but this association was found
by  other authors.29
The prevalence of HCV infection has been estimated
to have reached 10 million injected drug users worldwide,
whereas 1.2 million would have been infected by HBV.30 The
importance  of this lies on the fact that cART is less beneﬁcial
in  patients with coinfection, and adherence to therapy, which
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Fig. 3 – Survival analysis of AIDS patients according to the period of AIDS diagnosis ((A) 1986–1993, (B) 1994–1996, (C)
1997–2002, (D) 2003–2010) and the presence of hepatitis C virus coinfection.
Table 3 – Multivariate Cox model analysis of predictors
of  death, CRT DST/AIDS-SP, 1986–2010.
Patient’s characteristics n = 2.864 p-value
HR 95% CI
Agea
Up to 29 years old 1 – –
30–49 years old 1.2 0.9–1.7 0.258
50 years or older 2.3 1.3–3.8 0.002
Schooling (years)a,b
12 years or more 1 – –
8–11 1.6 1.1–2.3 0.017
4–7 1.9 1.3–2.8 0.001
Up to 3 3.3 2.0–5.5 <0.001
Hepatitis B (HBsAg)a
No 1 – –
Yes 2.4 1.7–3.6 <0.001
Hepatitis Ca
No 1 – –
Yes 2.7 2.0–3.6 <0.001
HR, hazard ratio; CI, conﬁdence interval; HBsAg, hepatitis B surface
antigen.
a In the diagnosis of AIDS.
b Unknown data = 58.is already a problem in HIV–HCV coinfected patients,6 can be
even  lower among drug users.31,32 A meta-analysis published
this  year has shown that treatment of addiction results in
higher  hepatitis treatment completion including antivirals.33
Another coinfection signiﬁcantly associated with
increased risk of death in our study was HBV–HIV coin-
fection, as already reported by other authors.34 HIV–HBV
coinfected individuals have accelerated hepatic ﬁbrosis and
reduced  rates of spontaneous resolution of acute infection
onset.35 But the inﬂuence of HBV infection in the course of
AIDS  is not known, and serological testing and vaccination
are  recommended to HIV infected individuals.
The association of increased survival and higher school-
ing  came as no surprise in this study, as it had been already
shown  by others,36 as well as the association with advanced
age,4,37,38 a ﬁnding which can be related to biological factors,
social stigma, quantity and quality of social relationships.39,40
We  did not ﬁnd signiﬁcant association of survival and gender
and  race in our study, but literature results are not consen-
sual  regarding this issue,41–43 and possibly it can be related to
social  factors such as access to care44,45 and adherence related
42,43to  gender.
The exclusion of dead patients who did not have HCV RNA
results  in the medical record and the exclusion of patients
with  late AIDS diagnosis (i.e. patients who died within 12
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months from diagnosis) may  have resulted in overestimation
of  survival rates and are limitations of this study.
Conclusions
Among patients diagnosed after 1996, there was  a signiﬁcant
increase in the cumulative probability of survival in HIV–HCV
coinfected patients compared to previous years, and among
those  receiving AIDS diagnosis in the period from 2003 to
2010,  this probability was  similar between coinfected and non-
coinfected patients, reﬂecting a possible impact of effective
treatment of hepatitis C and cART on survival.
The results of our study are important and relevant for the
clinical  management and clinical policies designed for people
living  with HIV.
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